Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.220
+0.030 (2.52%)
At close: Sep 18, 2026, 4:00 PM EDT
1.250
+0.030 (2.46%)
After-hours: Sep 18, 2026, 8:00 PM EDT
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 27 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year.
Employees
27
Change
n/a
Growth
n/a
Revenue / Employee
$1,299,630
Profits / Employee
$418,815
Market Cap
38.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 27 | 0 | - |
| Mar 31, 2026 | 25 | -6 | -19.35% |
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Celularity | 115 |
| Metagenomi Therapeutics | 113 |
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| Veru Inc. | 20 |
| CervoMed | 15 |
ATNM News
- 15 days ago - Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 17 days ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 5 weeks ago - Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PRNewsWire
- 6 weeks ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 6 weeks ago - Actinium Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 3 months ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 3 months ago - Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026 - TheFly
- 3 months ago - Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PRNewsWire